AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25172889 — intervention group
Group type: EXPERIMENTAL
Intervention: ET receptor blockade (bosentan)
Number of subjects: 18
Study 25172889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21737561 — intervention group
Group type: COMPARATOR
Intervention: Winter season
Number of subjects: 0
Study 21737561 — intervention group
Group type: COMPARATOR
Intervention: Moderate exacerbations
Number of subjects: 0
Study 21737561 — intervention group
Group type: COMPARATOR
Intervention: Severe exacerbations
Number of subjects: 0
Study 21737561 — intervention group
Group type: COMPARATOR
Intervention: Older age, lower body mass index, lower FEV(1) % pred, history of prior exacerbations
Number of subjects: 0
Study 21737561 — intervention group
Group type: COMPARATOR
Intervention: Female gender
Number of subjects: 0
Study 21737561 — intervention group
Group type: COMPARATOR
Intervention: MRC dyspnoea score 3 versus 1 and 2 combined
Number of subjects: 0
Study 21737561 — intervention group
Group type: COMPARATOR
Intervention: Seasonality effect
Number of subjects: 0
Study 19543687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-deficiency anemia and pagophagia with H. pylori infection before eradication
Number of subjects: 100
Study 19543687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-deficiency anemia and pagophagia after H. pylori eradication
Number of subjects: 100
Study 19543687 — intervention group
Group type: COMPARATOR
Intervention: Iron-deficiency anemia without pagophagia
Number of subjects: 100
Study 19543687 — intervention group
Group type: COMPARATOR
Intervention: Iron-deficiency anemia with pagophagia
Number of subjects: 100
Study 17689600 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal Web intervention
Number of subjects: 174
Study 17689600 — intervention group
Group type: COMPARATOR
Intervention: Standard Web site (control)
Number of subjects: 174
Study 15573192 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5mg/kg intravenous
Number of subjects: 60
Study 15573192 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 60
Study 11286152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 598
Study 9752650 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair of the supraspinatus tendon
Number of subjects: 4
Study 9752650 — intervention group
Group type: COMPARATOR
Intervention: Control case (intact musculotendinous unit)
Number of subjects: 4
Study 8118970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 250
Study 8118970 — intervention group
Group type: COMPARATOR
Intervention: Cementless total hip arthroplasty
Number of subjects: 250
Study 2898859 — intervention group
Group type: EXPERIMENTAL
Intervention: betaxolol 0.5% drops
Number of subjects: 41
Study 2898859 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.5% drops
Number of subjects: 41
Study 16321158 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg
Number of subjects: 617
Study 16321158 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg
Number of subjects: 617
Study 16321158 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg
Number of subjects: 617
Study 16321158 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 150 mg
Number of subjects: 617
Study 31904629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Liver Disease Nurse (CLDN) role
Number of subjects: 0
Study 31062731 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D serum level
Number of subjects: 47
Study 31062731 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR Fok1 polymorphism distribution
Number of subjects: 47
Study 31062731 — intervention group
Group type: COMPARATOR
Intervention: Control group VDR Fok1 polymorphism distribution
Number of subjects: 47
Study 27751603 — intervention group
Group type: EXPERIMENTAL
Intervention: EG1 (14.5 °C from 1 to 50 dph, then 20 °C until 176 dph)
Number of subjects: 120
Study 27751603 — intervention group
Group type: EXPERIMENTAL
Intervention: EG2 (14.5 °C from 1 to 37 dph, then 20 °C until 226 dph)
Number of subjects: 120
Study 27751603 — intervention group
Group type: COMPARATOR
Intervention: CG1 (15.0 °C for 10 dph, then 19.0 °C until 176 dph)
Number of subjects: 120
Study 27751603 — intervention group
Group type: COMPARATOR
Intervention: CG2 (15.0 °C for 10 dph, then 19.0 °C until 226 dph)
Number of subjects: 120
Study 26550815 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbo-pelvic core stabilization training (LPST)
Number of subjects: 25
Study 26550815 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with passive cycling (PC)
Number of subjects: 25
Study 26550815 — intervention group
Group type: COMPARATOR
Intervention: Controlled intervention with rest (CI)
Number of subjects: 25
Study 24376842 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned caesarean section at 38 weeks and three days
Number of subjects: 1274
Study 24376842 — intervention group
Group type: COMPARATOR
Intervention: Planned caesarean section at 39 weeks and three days
Number of subjects: 1274
Study 21705403 — intervention group
Group type: EXPERIMENTAL
Intervention: R2 (20 W to 90% LT bouts separated by 30 s at 20 W)
Number of subjects: 15
Study 21705403 — intervention group
Group type: EXPERIMENTAL
Intervention: S2 (two step increments in work rate)
Number of subjects: 15
Study 21705403 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 (two step increments in work rate)
Number of subjects: 15
Study 21705403 — intervention group
Group type: COMPARATOR
Intervention: F control bouts (two 20 W to 90% LT bouts separated by 12 min at 20 W)
Number of subjects: 15
Study 18212314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (diuretic)
Number of subjects: 38462
Study 18212314 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (calcium antagonist)
Number of subjects: 38462
Study 18212314 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (ACE inhibitor)
Number of subjects: 38462
Study 18212314 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin (alpha-blocker)
Number of subjects: 38462
Study 17068625 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia followed with postoperative intravenous analgesia (n=53)
Number of subjects: 103
Study 17068625 — intervention group
Group type: COMPARATOR
Intervention: Combined general-epidural anesthesia followed with postoperative epidural analgesia (n=50)
Number of subjects: 103
Study 12941494 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on generic drugs (verbal information and handout materials)
Number of subjects: 4620
Study 12941494 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic prescribing in intervention practices
Number of subjects: 4620
Study 12941494 — intervention group
Group type: COMPARATOR
Intervention: Generic prescribing in control practices
Number of subjects: 4620
Study 10642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables related to left ventricular systolic dysfunction
Number of subjects: 126
Study 10642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram with Q waves, left bundle branch block, or ST‐T segment changes
Number of subjects: 126
Study 10642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting supine heart rate greater than simultaneous diastolic blood pressure
Number of subjects: 126
Study 10642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma N‐terminal atrial natriuretic peptide >0.8 nmol/l
Number of subjects: 126
Study 10642232 — intervention group
Group type: COMPARATOR
Intervention: Normal electrocardiogram
Number of subjects: 126
Study 10642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Two or three positive responses to clinical questions
Number of subjects: 126
Study 9342765 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 mg LI 160/die
Number of subjects: 0
Study 9342765 — intervention group
Group type: COMPARATOR
Intervention: 150 mg imipramine/die
Number of subjects: 0
Study 7506580 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 115
Study 7506580 — intervention group
Group type: COMPARATOR
Intervention: IL-1
Number of subjects: 115
Study 7506580 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 115
Study 7506580 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 115
Study 3097159 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine (sufficient dose to cause maximum H1 receptor blockade)
Number of subjects: 0
Study 3097159 — intervention group
Group type: COMPARATOR
Intervention: Histamine (acting on the H1 receptor)
Number of subjects: 0
Study 31925317 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (IM) and hydroxychloroquine (HCQ)
Number of subjects: 62
Study 31925317 — intervention group
Group type: COMPARATOR
Intervention: Imatinib (IM) alone
Number of subjects: 62
Study 28836154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH, n = 40, nasopharyngeal temperature 25 °C, rectal temperature 28 °C)
Number of subjects: 82
Study 28836154 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia (MH)
Number of subjects: 82
Study 28836154 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermia (DH, n = 42, nasopharyngeal temperature 20 °C, rectal temperature 25 °C)
Number of subjects: 82
Study 28836154 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermia (DH)
Number of subjects: 82
Study 26036675 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (eight sessions of elbow manipulation and exercise)
Number of subjects: 165
Study 26036675 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection
Number of subjects: 165
Study 26036675 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection plus physiotherapy
Number of subjects: 165
Study 26036675 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 165
Study 25643201 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective thinking (higher levels of reflection) in individuals low in both mindfulness and memory specificity.
Number of subjects: 274
Study 25643201 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective thinking (higher levels of reflection) in all other groups (not low in mindfulness and memory specificity).
Number of subjects: 274
Study 23953523 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose tacrolimus plus sirolimus (rTAC)
Number of subjects: 128
Study 23953523 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose tacrolimus and sirolimus (sTAC)
Number of subjects: 128
Study 21131677 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory environments (MSEs)
Number of subjects: 30
Study 21131677 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 30
Study 17852727 — intervention group
Group type: EXPERIMENTAL
Intervention: Misinformation narrative
Number of subjects: 232
Study 17852727 — intervention group
Group type: COMPARATOR
Intervention: Control narrative
Number of subjects: 232
Study 17852727 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential retrieval order
Number of subjects: 232
Study 17852727 — intervention group
Group type: EXPERIMENTAL
Intervention: Random retrieval order
Number of subjects: 232
Study 17852727 — intervention group
Group type: EXPERIMENTAL
Intervention: Delay (2 weeks)
Number of subjects: 232
Study 15871445 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (Celebrex 200 mg, Pfizer, Turkey)
Number of subjects: 75
Study 15871445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 12635913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality salience
Number of subjects: 0
Study 11789239 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinitis Spray (RS)
Number of subjects: 80
Study 11789239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 80
Study 11789239 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 80
Study 9376336 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15 +/- 5 mg/day)
Number of subjects: 202
Study 9376336 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5 +/- 2.5 mg/day)
Number of subjects: 202
Study 9376336 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 +/- 2.5 mg/day)
Number of subjects: 202
Study 9376336 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (15 +/- 2.5 mg/day)
Number of subjects: 202
Study 9376336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 9376336 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (all doses)
Number of subjects: 202
Study 8258676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10-40 mg/day)
Number of subjects: 13
Study 8258676 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30-90 mg/day)
Number of subjects: 13
Study 8258676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3937666 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustak-forte preparation (nitroglycerin with prolonged action)
Number of subjects: 64
Study 3937666 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 64
Study 3937666 — intervention group
Group type: COMPARATOR
Intervention: No nitrates (control group)
Number of subjects: 64
Study 30675708 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg for 6 months
Number of subjects: 80
Study 30675708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 29246467 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Number of subjects: 197
Study 29246467 — intervention group
Group type: COMPARATOR
Intervention: Delayed cord clamping (DCC)
Number of subjects: 197
Study 29246467 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 197
Study 27407100 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-agent chemotherapy
Number of subjects: 218
Study 27407100 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combination arm
Number of subjects: 218
Study 27407100 — intervention group
Group type: COMPARATOR
Intervention: CA-125
Number of subjects: 218
Study 27407100 — intervention group
Group type: COMPARATOR
Intervention: Concordant PD by RECIST and CA-125
Number of subjects: 218
Study 25247944 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal Artifact Reduction (MAR) software
Number of subjects: 53
Study 25247944 — intervention group
Group type: COMPARATOR
Intervention: Standard reconstruction
Number of subjects: 53
Study 25247944 — intervention group
Group type: EXPERIMENTAL
Intervention: MAR reconstruction
Number of subjects: 53
Study 22537387 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration in pre-treated patients
Number of subjects: 0
Study 22537387 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo administration in drug-naïve patients
Number of subjects: 0
Study 22537387 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration in pre-treated patients (SP792 study)
Number of subjects: 0
Study 22537387 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine group responses
Number of subjects: 0
Study 20495588 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg intravenous ketamine infusion diluted in 500 cc normal saline over a 5 hour period daily for one week and 300 mg of gabapentin 3 times daily.
Number of subjects: 40
Study 20495588 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion and 300 mg of gabapentin 3 times daily.
Number of subjects: 40
Study 18833861 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF 5000 ppm (Prevident, Colgate)
Number of subjects: 21
Study 18833861 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva
Number of subjects: 21
Study 18833861 — intervention group
Group type: EXPERIMENTAL
Intervention: MI paste (Recaldent, GC America Inc)
Number of subjects: 21
Study 18833861 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF 1100 ppm (Crest, Procter & Gamble)
Number of subjects: 21
Study 18833861 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF 1100 ppm plus MI paste
Number of subjects: 21
Study 11696146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + clonidine 1 microg x kg(‐1)
Number of subjects: 75
Study 11696146 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine + clonidine 2 microg x kg(‐1)
Number of subjects: 75
Study 11696146 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone
Number of subjects: 75
Study 9209186 — intervention group
Group type: EXPERIMENTAL
Intervention: Substitute (sugar and coloring)
Number of subjects: 139
Study 9209186 — intervention group
Group type: COMPARATOR
Intervention: Coffee (continuation of coffee)
Number of subjects: 139
Study 8431046 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercostal bupivacaine (0.5% bupivacaine, 360 mg/day)
Number of subjects: 86
Study 8431046 — intervention group
Group type: COMPARATOR
Intervention: Intercostal saline solution (control group)
Number of subjects: 86
Study 8431046 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-schedule intramuscular buprenorphine
Number of subjects: 86
Study 2956864 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 1 mg/kg
Number of subjects: 12
Study 2956864 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone 2 mg/kg
Number of subjects: 12
Study 2956864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29746227 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg twice daily for 3 weeks, then 20 mg once daily for a total of 6 months)
Number of subjects: 406
Study 29746227 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin (200 IU/kg daily during month 1, then 150 IU/kg daily for months 2-6)
Number of subjects: 406
Study 29746227 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 406
Study 29746227 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 406
Study 28497265 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic analysis of pleomorphic adenoma (PA)
Number of subjects: 13
Study 26219538 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-Sal novel mDPI 100 μg-50 μg
Number of subjects: 555
Study 26219538 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-Sal novel mDPI 500 μg-50 μg
Number of subjects: 555
Study 26219538 — intervention group
Group type: COMPARATOR
Intervention: FP-Sal novel mDPI
Number of subjects: 555
Study 26219538 — intervention group
Group type: COMPARATOR
Intervention: Originator device 100 μg-50 μg
Number of subjects: 555
Study 26219538 — intervention group
Group type: COMPARATOR
Intervention: Originator device 500 μg-50 μg
Number of subjects: 555
Study 26219538 — intervention group
Group type: EXPERIMENTAL
Intervention: FP-Sal novel mDPI and originator device
Number of subjects: 555
Study 23938309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine (mean dose 2.3 mg)
Number of subjects: 55
Study 23938309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 23938309 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled apomorphine
Number of subjects: 55
Study 21074015 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 0.75 mg, two doses 12 hours apart during the preovulatory phase
Number of subjects: 30
Study 21074015 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (untreated)
Number of subjects: 30
Study 18470753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16768683 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde intramedullary nail fixation (IM group)
Number of subjects: 22
Study 16768683 — intervention group
Group type: COMPARATOR
Intervention: Fixed-angle blade plate fixation (BP group)
Number of subjects: 22
Study 14651283 — intervention group
Group type: EXPERIMENTAL
Intervention: MTAD (2-h treatment)
Number of subjects: 8
Study 14651283 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 8
Study 14651283 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% NaOCl
Number of subjects: 8
Study 14651283 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 10807816 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol MDI plus spacer (correct use)
Number of subjects: 20
Study 10807816 — intervention group
Group type: COMPARATOR
Intervention: MDI alone (incorrect use)
Number of subjects: 20
Study 8816295 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex febrile seizures (CFS)
Number of subjects: 105
Study 8816295 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple febrile seizures (SFS)
Number of subjects: 105
Study 8816295 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 1428307 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial meniscectomy
Number of subjects: 200
Study 1428307 — intervention group
Group type: EXPERIMENTAL
Intervention: Total meniscectomy
Number of subjects: 200
Study 30623568 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips single‐electric pump, Natural bottle
Number of subjects: 112
Study 30623568 — intervention group
Group type: EXPERIMENTAL
Intervention: Medela Swing single‐electric pump, Calma bottle
Number of subjects: 112
Study 30623568 — intervention group
Group type: COMPARATOR
Intervention: Control; vouchers
Number of subjects: 112
Study 28050988 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezoelectric osteotomy technique
Number of subjects: 30
Study 28050988 — intervention group
Group type: COMPARATOR
Intervention: Rotary osteotomy technique
Number of subjects: 30
Study 26944385 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam (0.15 mg/kg)
Number of subjects: 40
Study 26944385 — intervention group
Group type: COMPARATOR
Intervention: tramadol (1 mg/kg)
Number of subjects: 40
Study 24300544 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 200
Study 24300544 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week antiretroviral therapy (ART)
Number of subjects: 200
Study 24300544 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-week antiretroviral therapy (ART)
Number of subjects: 200
Study 21986807 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + PRO
Number of subjects: 14
Study 21986807 — intervention group
Group type: COMPARATOR
Intervention: CHO
Number of subjects: 14
Study 21986807 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + CAF
Number of subjects: 14